Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Holding(s) in Company

24 Nov 2016 07:30

RNS Number : 9985P
GW Pharmaceuticals PLC
24 November 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

GW Pharmaceuticals PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

x

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: iii

The Goldman Sachs Group, Inc.

4. Full name of shareholder(s) (if different from 3.):iv

Goldman Sachs International

Goldman, Sachs & Co.

Goldman Sachs Asset Management, L.P.

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

18 November 2016

6. Date on which issuer notified:

22 November 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

Below 3%

     
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

GB0030544687

94,532

94,532

 

 

Below 3%

 

Below 3%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

Below 3%

Below 3%

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

 

 

 

 

Below 3%

 

Below 3%

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

Below 3%

Below 3%

             

 

 

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

N/A

 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

 

13. Additional information:

General email contact:

shareholderdisclosures@gs.com

 

14. Contact name:

Joanna Foley

15. Contact telephone number:

+44 207 051 9996

 

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAPFDAEAKFFF
Date   Source Headline
22nd Jun 20162:22 pmRNSHolding(s) in Company
21st Jun 201612:00 pmRNSEpidiolex Development Program in Infantile Spasms
17th Jun 20165:05 pmRNSHolding(s) in Company
8th Jun 20164:54 pmRNSHolding(s) in Company
31st May 20161:25 pmRNSTotal Voting Rights
31st May 201612:00 pmRNSPresents at Goldman Sachs and Jefferies Conference
16th May 201612:00 pmRNSGWP presenting at UBS Global Healthcare Conference
13th May 20163:50 pmRNSDirector/PDMR Shareholding
11th May 20165:19 pmRNSDirector/PDMR Shareholding
5th May 201612:00 pmRNSHalf-year Report
4th May 201612:00 pmRNSPresenting at BoAML 2016 Healthcare Conference
29th Apr 20161:37 pmRNSTotal Voting Rights
28th Apr 201612:00 pmRNSNotice of Results
21st Apr 201612:00 pmRNSOrphan Drug Designation for Cannabidiol in TSC
11th Apr 201612:00 pmRNSInitiates Ph 3 Study in Tuberous Sclerosis Complex
1st Apr 20163:24 pmRNSDirector/PDMR Shareholding
23rd Mar 20165:07 pmRNSResult of AGM
18th Mar 20163:34 pmRNSBlock Listing Application
14th Mar 201611:00 amRNSEpidiolex Positive Phase 3 Pivotal Study Results
29th Feb 20169:26 amRNSTotal Voting Rights
22nd Feb 20166:16 pmRNSNotice of AGM
17th Feb 201610:37 amRNSBlocklisting Interim Review
15th Feb 20162:39 pmRNSDirector/PDMR Shareholding
10th Feb 201612:00 pmRNS1st Quarter Results
4th Feb 20163:45 pmRNSPresenting at Leerink Global Healthcare Conference
2nd Feb 20163:07 pmRNSNotice of Results
29th Jan 201611:42 amRNSTotal Issued Share Capital
29th Jan 20169:29 amRNSHolding(s) in Company
28th Jan 20168:47 amRNSHolding(s) in Company
25th Jan 20168:33 amRNSHolding(s) in Company
6th Jan 201612:01 pmRNSPublication of UK Annual Report and Accounts
31st Dec 201510:42 amRNSTOTAL ISSUED SHARE CAPITAL
29th Dec 20152:26 pmRNSDirector/PDMR Shareholding
24th Dec 201512:00 pmRNSLancet Neurology Publishes Epidiolex Data
22nd Dec 20155:14 pmRNSDirector/PDMR Shareholding
21st Dec 20156:22 pmRNSDirector/PDMR Shareholding
16th Dec 20154:16 pmRNSDirector/PDMR Shareholding
16th Dec 20159:27 amRNSDirector/PDMR Shareholding
8th Dec 20157:00 amRNSFinal Results
7th Dec 20156:00 pmRNSNew Physician Reports of Epidiolex Treatment
30th Nov 20151:00 pmRNSDate and Time Change for Q4 and FY 2015 Results
30th Nov 20159:38 amRNSTotal Voting Rights
25th Nov 20152:00 pmRNSEpidiolex data to be presented at AES Meeting
24th Nov 20156:00 pmRNSNotice of Results
24th Nov 20156:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
2nd Nov 201510:09 amRNSTotal Voting Rights
27th Oct 201511:05 amRNSAgreement with NSW to Study Epidiolex and CBDV
27th Oct 201511:00 amRNSResults from Sativex Phase 3 Cancer Pain Trials
15th Sep 20152:00 pmRNSPositive Proof of Concept Data in Schizophrenia
10th Sep 20152:00 pmRNSPresenting at Two Upcoming Investor Conferences

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.